Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies

Current Hematologic Malignancy Reports
Rebecca Karp LeafDavid Avigan

Abstract

Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (allo-HCT) and donor lymphocyte infusion (DLI), demonstrate long-term disease control via manipulation of the immunologic milieu. However, allo-HCT is associated with numerous toxicities including infectious complications and graft versus host effect and is not suitable for many patients. Novel agents and cellular-based therapies aim to restore the balance of humoral and adaptive immunity without the morbidity of allo-HCT and DLI. In the following review, we will summarize the use of immunomodulatory techniques in multiple myeloma, including monoclonal antibodies, vaccine therapy, checkpoint inhibitors, autologous T cells, and engineered T cells.

References

Jun 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·R G LynchH N Eisen
Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G GahrtonP Jacobs
Aug 7, 2001·Seminars in Hematology·W I BensingerR Storb
Jun 28, 2002·Nature Immunology·Jackson G EgenJames P Allison
Nov 26, 2002·Immunological Reviews·Matthew J ScanlanYao-Tseng Chen
Apr 26, 2003·Blood·Toshiaki HayashiKenneth C Anderson
Dec 2, 2004·Nature Reviews. Immunology·Dmitry Gabrilovich
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jianfei QianQing Yi
Jan 31, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Leona HolmbergGeorge B McDonald
Aug 2, 2006·The Journal of Experimental Medicine·Anjli KukrejaMadhav V Dhodapkar
Aug 24, 2006·Expert Review of Anticancer Therapy·Paul G RichardsonKenneth C Anderson
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Deirdre O'MahonyJohn E Janik
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lotta HanssonHåkan Mellstedt
Mar 16, 2007·The New England Journal of Medicine·Benedetto BrunoMario Boccadoro
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John KuruvillaKevín W Song
Jul 10, 2008·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM)
Feb 7, 2009·Nature Reviews. Immunology·Dmitry I Gabrilovich, Srinivas Nagaraj
Sep 11, 2009·Leukemia·J J Shah, R Z Orlowski
Oct 8, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen M AnsellJohn M Timmerman
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L FerrisSoldano Ferrone
Oct 22, 2010·Cancer Immunology, Immunotherapy : CII·Jürgen KuballMatthias Theobald
Dec 29, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michel de WeersPaul W H I Parren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.